Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hematology and Cell Therapy
Published in: Hematology and Cell Therapy 2/1997

01-04-1997 | Review article

The ex vivo expansion capacity of normal human bone marrow cellsis dependent on experimental conditions: role of the cell concentration, serum and CD34+ cell selection in stroma-free cultures

Authors: A. Poloni, M. C. Giarratana, H. Firat, L. Kobari, N. C. Gorin, L. Douay

Published in: Hematology and Cell Therapy | Issue 2/1997

Login to get access
Metadata
Title
The ex vivo expansion capacity of normal human bone marrow cellsis dependent on experimental conditions: role of the cell concentration, serum and CD34+ cell selection in stroma-free cultures
Authors
A. Poloni
M. C. Giarratana
H. Firat
L. Kobari
N. C. Gorin
L. Douay
Publication date
01-04-1997
Publisher
Springer Paris
Published in
Hematology and Cell Therapy / Issue 2/1997
Print ISSN: 1269-3286
Electronic ISSN: 1279-8509
DOI
https://doi.org/10.1007/s00282-997-0049-9

Other articles of this Issue 2/1997

Hematology and Cell Therapy 2/1997 Go to the issue

6th Cell Therapy Workshop AMGEN-ROCHE

Dysregulated Mpl-Ligand production by hemopoietic cellsinduces a fatal myeloproliferative syndrome in mice

6th Cell Therapy Workshop AMGEN-ROCHE

The use of cytokines in the treatment of solid tumours

Original article

Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin’s disease (stage I, II and IIIA)

6th Cell Therapy Workshop AMGEN-ROCHE

Gène de l’érythropoïétine : régulation et intérêt thérapeutique

6th Cell Therapy Workshop AMGEN-ROCHE

Suppression or overexpression of genes encoding myeloid growth factors or their receptors

Original article

Expression of CD95(Fas) by gene transfer does not sensitize K562 to Fas-killing
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits